<ul data-eligibleForWebStory="false"><li>The United States under the Trump administration halted all HIV vaccine research funding in South Africa, impacting global health initiatives.</li><li>The termination of a $46 million project called BRILLIANT has caused devastation among researchers in a region heavily affected by HIV, jeopardizing progress in the fight against the disease.</li><li>The cuts threaten South Africa's essential role in HIV research and development of vital medications, including lenacapavir, impacting not only local employment but also global advancements in health care.</li><li>Thousands of researchers and health workers have been laid off, jeopardizing crucial projects addressing HIV and tuberculosis, ultimately leading to increased HIV infections and challenges in accessing medication and healthcare services.</li></ul>

US aid cuts halt HIV vaccine research in South Africa, with global impact

Discover more